VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | Drug repurposing in HER2+ breast cancer

Erica Michelle Stringer-Reasor, MD, University of Alabama at Birmingham, Birmingham, AL, explores the repurposing of treatments for HER2-positive breast cancer that are not FDA-approved for the subtype of breast cancer. Resistance to current HER2-positive breast cancer treatments has led to the need for developing novel therapies, with the repurposing of existing breast cancer treatments not specifically approved for HER2-positive breast cancer. One such trial is the ongoing Phase I/IIb trial (NCT03368729) of niraparib, a PARP inhibitor, in combination with trastuzumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter